Tau Spread, Apolipoprotein E, Inflammation, and More : Rapidly Evolving Basic Science in Alzheimer Disease - 14/12/17
Doi : 10.1016/j.ncl.2017.01.001
Bianca Gonzalez, PhD, MS, FNP-BC, RN a, Edsel M. Abud, BS b, Abigail M. Abud, BS b, Wayne W. Poon, PhD b, Karen H. Gylys, PhD, RN a, ⁎ 
a UCLA School of Nursing, Box 956919, Factor Building 6-266, Los Angeles, CA 90095, USA
b Institute for Memory Impairments and Neurological Disorders, UC Irvine, 2642 Biological Sciences III, Irvine, CA 92697-4545, USA
∗Corresponding author.
Résumé |
To date, Alzheimer disease drug candidates have produced negative results in human trials, and progress in moving new targets out of the laboratory and into trials has been slow. However, based on 3 decades of previous work, there is reason to hope that amyloid-based and other novel therapies will move at a faster pace toward successful clinical trials. This article highlights selected preclinical research topics that are rapidly advancing in the laboratory.
Le texte complet de cet article est disponible en PDF.Keywords : Imaging flow cytometry, Oligomer, Synapse, Cholesterol, Microglia
Plan
| Funded by: National Institutes of Health grant numbers: P50 AG05142, P50 AG16970, R56 AG027465; NIHMS-ID: 843123. |
© 2017
Elsevier Inc. Tous droits réservés.
Vol 35 - N° 2
P. 175-190 - mai 2017 Retour au numéro
Article précédent
- Update on Alzheimer’s and the Dementias : Introduction
- John M. Ringman
- The Role of Neuropsychology in the Assessment of the Cognitively Impaired Elderly
- Po H. Lu, Grace J. Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?